Lilly and Daiichi Sankyo's prasugrel NDA gets priority review - Pharma Times (subscription)
The NDA for prasugrel, which if approved will compete with Plavix (clopidogrel), Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster, was submitted to the ...